Gregg Peterson

Gregg has 20+ years of experience developing pharmaceutical, medical device, biologic and combination products, leading to the launch of 12 products globally. He is currently co-founder and CEO of Bexson Biomedical, a biotech developing subcutaneous formulation technology and a wearable device for several psychedelic compounds. He was previously a Global R&D Program Lead for S&P500 company with a focus on US, EU and AsiaPac. He has a successful history directing R&D programs from market need analysis and ideation, through Phase III clinical trials, and to regulatory approval. Gregg is a veteran of multiple startup companies including Evolus (IPO), TargeGen (sale to Sanofi-Aventis) and Somaxon (IPO). He holds a B.S. from University of Puget Sound and a M.A. from the Medical College of Wisc.